HHS Public Access Author manuscript Author Manuscript
Cancer. Author manuscript; available in PMC 2017 October 01. Published in final edited form as: Cancer. 2016 October ; 122(19): 2988–2995. doi:10.1002/cncr.30146.
Racial disparities in survival in advanced renal cell carcinoma in the targeted therapy era Tracy L. Rose, M.D. M.P.H.1,3, Allison M. Deal, M.S.2, Bhavani Krishnan, PhD.3, Matthew E. Nielsen, M.D. M.S.3,4,5,6, Angela B. Smith, M.D. M.S.3,4, William Y. Kim, M.D.1,2, and Matthew I. Milowsky, M.D.1,3 1Division
Author Manuscript
of Hematology/Oncology, Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 2Biostatistics
and Clinical Data Management Core, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
3University
of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
4Urologic
Oncology Program, Department of Urology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
5Department
of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC
6Department
of Health Policy and Management, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC
Author Manuscript
Abstract Background—African American (AA) patients with renal cell cancer (RCC) have historically had inferior survival compared to Caucasian patients. Recent studies suggest the survival disparity between races may be worsening since the advent of targeted therapies for RCC. This study examines survival rates of AA and Caucasian patients with advanced RCC over time to determine if a disparity in survival persists in the targeted therapy era. Methods—We identified patients with stage IV RCC in the National Cancer Data Base (NCDB) and compared survival between AA and Caucasian patients in the time periods before (1998-2004) and after (2006-2011) the advent of targeted therapy.
Author Manuscript
Corresponding Author: Matthew I. Milowsky, Division of Hematology/Oncology, University of North Carolina, 3rd Floor Physician's Office Building, 170 Manning Drive, Chapel Hill, NC 27599, (tel) 919-843-7942, (fax) 919-966-6735, [email protected]. 919-966-1996, [email protected] [email protected] [email protected] [email protected] [email protected] [email protected] Author Contributions: T.L.R., W.Y.K., and M.I.M. were involved in conception and design, analysis and interpretation of data, drafting and revising the manuscript, and final approval of the manuscript. A.M.D., B.K., and M.E.N. were involved in analysis and interpretation of data, drafting and revising the manuscript, and final approval of the manuscript. A.B.S. was involved in conception and design, drafting and revising the manuscript, and final approval of the manuscript. Conflict of Interest: The authors have no other conflicts of interest to disclose.
Rose et al.
Page 2
Author Manuscript
Results—48,846 patients were identified and 10% were AA. 3-year survival of both AA and Caucasian patients improved between the two time periods (p
Cancer. Author manuscript; available in PMC 2017 October 01. Published in final edited form as: Cancer. 2016 October ; 122(19): 2988–2995. doi:10.1002/cncr.30146.
Racial disparities in survival in advanced renal cell carcinoma in the targeted therapy era Tracy L. Rose, M.D. M.P.H.1,3, Allison M. Deal, M.S.2, Bhavani Krishnan, PhD.3, Matthew E. Nielsen, M.D. M.S.3,4,5,6, Angela B. Smith, M.D. M.S.3,4, William Y. Kim, M.D.1,2, and Matthew I. Milowsky, M.D.1,3 1Division
Author Manuscript
of Hematology/Oncology, Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 2Biostatistics
and Clinical Data Management Core, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
3University
of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
4Urologic
Oncology Program, Department of Urology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
5Department
of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC
6Department
of Health Policy and Management, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC
Author Manuscript
Abstract Background—African American (AA) patients with renal cell cancer (RCC) have historically had inferior survival compared to Caucasian patients. Recent studies suggest the survival disparity between races may be worsening since the advent of targeted therapies for RCC. This study examines survival rates of AA and Caucasian patients with advanced RCC over time to determine if a disparity in survival persists in the targeted therapy era. Methods—We identified patients with stage IV RCC in the National Cancer Data Base (NCDB) and compared survival between AA and Caucasian patients in the time periods before (1998-2004) and after (2006-2011) the advent of targeted therapy.
Author Manuscript
Corresponding Author: Matthew I. Milowsky, Division of Hematology/Oncology, University of North Carolina, 3rd Floor Physician's Office Building, 170 Manning Drive, Chapel Hill, NC 27599, (tel) 919-843-7942, (fax) 919-966-6735, [email protected]. 919-966-1996, [email protected] [email protected] [email protected] [email protected] [email protected] [email protected] Author Contributions: T.L.R., W.Y.K., and M.I.M. were involved in conception and design, analysis and interpretation of data, drafting and revising the manuscript, and final approval of the manuscript. A.M.D., B.K., and M.E.N. were involved in analysis and interpretation of data, drafting and revising the manuscript, and final approval of the manuscript. A.B.S. was involved in conception and design, drafting and revising the manuscript, and final approval of the manuscript. Conflict of Interest: The authors have no other conflicts of interest to disclose.
Rose et al.
Page 2
Author Manuscript
Results—48,846 patients were identified and 10% were AA. 3-year survival of both AA and Caucasian patients improved between the two time periods (p
